{"id":"https://openalex.org/W7204690095","doi":"https://doi.org/10.1016/s2152-2650(26)02531-0","title":"ABCL-100: Comparative Pharmacovigilance of CD20-Directed Bispecific Antibodies in B-Cell Lymphoma: A FAERS Observational Study","display_name":"ABCL-100: Comparative Pharmacovigilance of CD20-Directed Bispecific Antibodies in B-Cell Lymphoma: A FAERS Observational Study","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204690095","doi":"https://doi.org/10.1016/s2152-2650(26)02531-0"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)02531-0","doi":"https://doi.org/10.1016/s2152-2650(26)02531-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02531-0","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W7204690095"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5148708064","display_name":"Edward Mwarangu","orcid":"https://orcid.org/0009-0007-9377-9218","observed_orcids":["https://orcid.org/0009-0007-9377-9218"]},"institutions":[{"id":"https://openalex.org/I146416000","display_name":"University of Kansas","ror":"https://ror.org/001tmjg57","country_code":"US","type":"education","lineage":["https://openalex.org/I146416000"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edward Mwarangu","raw_affiliation_strings":["University of Kansas, Wichita, KS, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Kansas, Wichita, KS, USA","institution_ids":["https://openalex.org/I146416000"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052399248","display_name":"Bassam Muthanna","orcid":"https://orcid.org/0000-0002-9594-0964","observed_orcids":["https://orcid.org/0000-0002-9594-0964"]},"institutions":[{"id":"https://openalex.org/I76835614","display_name":"University of Missouri","ror":"https://ror.org/02ymw8z06","country_code":"US","type":"education","lineage":["https://openalex.org/I76835614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bassam Muthanna","raw_affiliation_strings":["University of Missouri-Columbia, Columbia, MO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Missouri-Columbia, Columbia, MO, USA","institution_ids":["https://openalex.org/I76835614"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5117570041","display_name":"Moza Hamoud","orcid":"https://orcid.org/0009-0004-7314-247X","observed_orcids":["https://orcid.org/0009-0004-7314-247X"]},"institutions":[{"id":"https://openalex.org/I1327543694","display_name":"Eisenhower Medical Center","ror":"https://ror.org/050wjeh45","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1327543694"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moza Hamoud","raw_affiliation_strings":["Eisenhower Health, Rancho Mirage, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eisenhower Health, Rancho Mirage, CA, USA","institution_ids":["https://openalex.org/I1327543694"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077884550","display_name":"Nahid Suleman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I76835614","display_name":"University of Missouri","ror":"https://ror.org/02ymw8z06","country_code":"US","type":"education","lineage":["https://openalex.org/I76835614"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nahid Suleman","raw_affiliation_strings":["University of Missouri, Columbia, MO, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Missouri, Columbia, MO, USA","institution_ids":["https://openalex.org/I76835614"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S886","last_page":"S886"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.02630000002682209,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/b-cell-lymphoma","display_name":"B-cell lymphoma","score":0.9309999942779541},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.8939999938011169},{"id":"https://openalex.org/keywords/mosunetuzumab","display_name":"mosunetuzumab","score":0.972000002861023},{"id":"https://openalex.org/keywords/epcoritamab","display_name":"epcoritamab","score":1.0},{"id":"https://openalex.org/keywords/glofitamab","display_name":"glofitamab","score":1.0},{"id":"https://openalex.org/keywords/cytokine-release-syndrome","display_name":"cytokine release syndrome","score":0.9259999990463257},{"id":"https://openalex.org/keywords/neurologic-toxicity","display_name":"neurologic toxicity","score":0.9890000224113464},{"id":"https://openalex.org/keywords/adverse-event-reporting","display_name":"adverse event reporting","score":0.4869999885559082},{"id":"https://openalex.org/keywords/comparative-drug-safety","display_name":"drug safety comparison","score":0.7089999914169312},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.7929999828338623},{"id":"https://openalex.org/keywords/hospitalization","display_name":"hospitalization","score":0.527999997138977},{"id":"https://openalex.org/keywords/death","display_name":"death","score":0.6209999918937683},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.9309999942779541},{"id":"https://openalex.org/keywords/reporting-odds-ratio","display_name":"reporting odds ratio","score":0.5299999713897705}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9664000272750854},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.7961999773979187},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.6766999959945679},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.5986999869346619},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5006999969482422},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45989999175071716},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.41769999265670776},{"id":"https://openalex.org/C3018095205","wikidata":"https://www.wikidata.org/wiki/Q55641553","display_name":"Real world evidence","level":2,"score":0.36739999055862427},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.3497999906539917},{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.32580000162124634},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.260699987411499}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/s2152-2650(26)02531-0","doi":"https://doi.org/10.1016/s2152-2650(26)02531-0","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02531-0","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7215945108","https://openalex.org/W7166653969","https://openalex.org/W7204710324","https://openalex.org/W7162410966","https://openalex.org/W7204689216","https://openalex.org/W4414893215","https://openalex.org/W4405041869","https://openalex.org/W7204689444","https://openalex.org/W4417013445","https://openalex.org/W7168405606"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-08-31T00:00:00"}